Atypical Femur Fractures in Post-Menopausal Patients Taking Bisphosphonates and Their Indication When to Start after Holiday Period of 5 Years and Its Effects
Bibliographic record
Abstract
Postmenopausal women are at risk of fractures owing to osteoporosis, which is worsened by low oestrogen. Bisphosphonates like ibandronate, zoledronic acid, alendronate, and risedronate limit bone resorption and increase bone density, reducing fracture risk. Although atypical femur fractures (AFFs) are uncommon, they are associated with dangerous complications of long-term bisphosphonate therapy. Early fracture identification before they occur is crucial to minimizing complications. The review examines bisphosphonate-related medical issues in postmenopausal women with atypical femur fractures. The study also addressed whether to resume bisphosphonate medication following a pharmacological holiday, which reduces fracture risk. A thorough literature search was undertaken using PubMed, Embase, and the Cochrane Library. The search criteria included atypical femur fractures, bisphosphonates, osteoporosis, and therapy duration. Following screening, studies fulfilling inclusion criteria were assessed utilizing the Cochrane Risk of Bias Tool and Newcastle-Ottawa Scale. Several studies examined the association between long-term bisphosphonate usage and atypical femur fractures. Bisphosphonates reduce osteoporotic fractures but may raise AFF risk over time. The studies also emphasize the significance of individualized bisphosphonate treatment programs and thorough monitoring, especially after a medication holiday. Bisphosphonates reduce fracture risk, although atypical femur fractures require cautious treatment duration and timing, especially following a medication holiday. Selection bias and confounding variables may have limited the evidence of this research. The research design and use of real-world data may also affect its validity and reliability. To enhance treatment recommendations and patient outcomes, longitudinal research on bisphosphonates’ long-term impact on bone health and fracture risk is needed.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".